The same effects were observed with DPP-4 inhibitors (sitagliptin (A10BH01), alogliptin (A10BH04), teneligliptin (A10BH08)), where all three agents inhibited AAA progression significantly [22,23,24]. Here, DPP4 is linked to triple-A syndrome.